ArticleBMC cancer2025
Consolidative thoracic radiotherapy improves the prognosis of metastatic esophageal cancer in the chemoimmunotherapy era: a propensity score matching study.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundThe role of consolidative thoracic radiotherapy in patients with metastatic esophageal cancer receiving chemotherapy combined with immunotherapy is unclear. This study aimed to evaluate the efficacy and safety of consolidative thoracic radiotherapy combined with chemotherapy and immunotherapy for metastatic esophageal cancer.
methodsA multicenter retrospective study included 156 patients with metastatic esophageal cancer admitted between 2018 and 2023.Patients were divided into RT and non-RT groups based on whether they received consolidative thoracic radiotherapy. Propensity score matching (PSM) was used to reduce selection bias. Survival curves were compared using the log-rank test, and Kaplan-Meier survival curves were plotted. The primary endpoints were overall survival (OS) and progression-free survival (PFS).
resultsA total of 156 patients were reviewed, and 32 were matched in each group. After PSM, the median OS of the RT group was 38 months (95% CI 16.7–NA), while the median OS of the NRT group was 13.7 months (95% CI 9.0–NA) (95%CI 0.35–1.40) (HR: 0.7, p = 0.32). The median PFS in the RT group was not reached (95% CI 16.7–NA), and the median PFS in the NRT group was 9.3 months (95% CI 7.5–NA) (HR 0.62 95% CI 0.30–1.29, p = 0.17). The OS of the RT group was higher than that of the NRT group, although there was no statistical significance. Cox univariate and multivariate regression analysis showed that cervical tumor was an independent risk factor for OS and PFS (p < 0.05). The incidence of grade 1–2 pneumonia in the RT group was higher than that in the NRT group (p < 0.05), and there was no pneumonia of grade ≥ 3 in both groups. No treatment-related deaths occurred.
conclusionConsolidative thoracic radiotherapy combined with chemoimmunotherapy is a viable and safe treatment option for metastatic esophageal cancer and should be further validated in larger trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.